Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: FASEB J. 2022 Sep;36(9):e22482. doi: 10.1096/fj.202101398R

FIGURE 7.

FIGURE 7

BMAL1 and HNF4α loss is protective in the STAM model and SR9009 blocks invasion of BMAL1-expressing tumor cells. (A) Experimental timeline for STAM model on the BHLivDKO background. (B) Whole livers of VEH and STZ treated STAM mice (WT/ BHLivDKO) at 17 weeks of age (left panel), and percent tumor incidence and number of tumors per liver (right panel). (C–E) H&E, AFP, and oil-Red O staining of WT and, BHLivDKO, and H4LivKO mouse livers after VEH or STZ injection followed by HFD AT 16 weeks (scale bar = 2000 μm, magnified scale bar = 100 μm, 200 μm).